Biomarkers: Tool to identify the Women at increased stroke risk

The Women's Health Initiative hormone trials identified a 44% increase in ischemic stroke risk with combination estrogen plus progestin and a 39% increase with estrogen alone. We undertook a case-control biomarker study to elucidate underlying mechanisms, and to potentially identify women who would be at lower or higher risk for stroke with postmenopausal hormone therapy (HT).

 

    Related Conference of Biomarkers: Tool to identify the Women at increased stroke risk

    May 30-31, 2024

    23rd International Congress on Nutrition and Health

    Amsterdam, Netherlands
    June 27-29, 2024

    5th World Summit on Food and Nutrition

    London, UK
    August 08-09, 2024

    6th World Summit on Health Nutrition

    London, UK
    October 21-22, 2024

    28th World Congress on Nutrition and Food Sciences

    Paris, France
    November 28-29, 2024

    Food Safety Meet 2024

    Bali, Indonesia
    November 28-29, 2024

    7th World Congress on Food and Nutrition

    Bali, Indonesia

    Biomarkers: Tool to identify the Women at increased stroke risk Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in